Background-Ventricular tachycardia (VT) substrate ablation usually requires extensive ablation. Scar dechanneling technique may limit the extent of ablation needed. Methods and Results-The study included 101 consecutive patients with left ventricular scar-related VT (75 ischemic patients; left ventricular ejection fraction, 36±13%). Procedural end point was the elimination of all identified conducting channels (CCs) by ablation at the CC entrance followed by abolition of residual inducible VTs. By itself, scar dechanneling rendered noninducibility in 54.5% of patients; ablation of residual inducible VT increased noninducibility to 78.2%. Patients needing only scar dechanneling had a shorter procedure (213±64 versus 244±71 minutes; P=0.027), fewer radiofrequency applications (19±11% versus 27±18%; P=0.01), and external cardioversion/defibrillation shocks (20% versus 65.2%; P<0.001). At 2 years, patients needing scar dechanneling alone had better event-free survival (80% versus 62%) and lower mortality (5% versus 11%). Incomplete CC-electrogram elimination was the only independent predictor (hazard ratio, 2.54 [1.06-6.10]) for the primary end point. Higher end point-free survival rates were observed in patients noninducible after scar dechanneling (log-rank P=0.013) and those with complete CC-electrogram elimination (log-rank P=0.013). The complications rate was 6.9%, with no deaths. Conclusions-Scar dechanneling alone results in low recurrence and mortality rates in more than half of patients despite the limited ablation extent required. Residual inducible VT ablation improves acute results, but patients who require it have worse outcomes. Recurrences are mainly related to incomplete CC-electrogram elimination. (Circ Arrhythm Electrophysiol. 2015;8:326-336.
A cute results and long-term outcomes of conventional ventricular tachycardia (VT) ablation in patients with left ventricular (LV) scar-related VTs are suboptimal. The reported noninducibility rate of sustained monomorphic VT after ablation ranges from 38% to 73% of patients, and this translates into a high recurrence rate, ie, 50% to 88% during a follow-up of ≥12 months, despite the use of antiarrhythmic drugs. 1 Acute prevention of VT inducibility after catheter ablation is related to a lower, though still significant, VT recurrence rate during follow-up. 2 Therefore, noninducibility seems a desirable but insufficient acute end point.
A further step in reducing recurrences after ablation could be the complete elimination of all the substrates responsible for VT occurrence, a strategy based on the assumption that the substrate not participating in VTs at the time of ablation could activate and become part of a VT isthmus during follow-up. Recent reports have shown that substrate elimination, independent of participation or not as a VT circuit during the procedure, can be used as an acute endpoint [3] [4] [5] ; however, extensive ablation is still required, 4 the best technique for its elimination has not yet been described, and recurrences remain high. 5 In addition, the results obtained by substrate ablation as the first step during the ablation procedure for scar-related VTs are not yet known; in previous studies, the protocol started with VT induction and attempted the ablation of sustained and tolerated VTs. 4, 5 Substrate mapping during sinus or paced rhythm permits the characterization of scar areas supporting possible reentry circuits of VTs, called conducting channels (CCs). 6 These CCs can be identified by voltage mapping or electrogram analysis [7] [8] [9] and are considered the ablation target. 1 More specifically, in small series of patients with arrhythmogenic cardiomyopathy and ischemic cardiomyopathy, it has been suggested that radiofrequency applications at the CC entrance (the scar dechanneling technique) can homogenize the scar without extensive ablation and could possibly increase the ablation efficiency. [7] [8] [9] [10] We hypothesized that scar dechanneling is a feasible first step (before VT induction and ablation attempt) for patients with LV scar-related VT, and for many patients, it can result in less extensive ablation and no ventricular arrhythmia during the procedure. We report the procedure details and outcomes of this strategy.
Methods

Patient Sample
All consecutive patients (n=101) undergoing LV scar-related VT ablation at a single center from November 2009 to April 2013 were prospectively included in the study and followed up. Inclusion criteria were the presence of structural heart disease-previous myocardial infarction, LV dilatation/systolic dysfunction, or normal LV diameters/ systolic function with evidence of ventricular scar on contrast enhanced-cardiac magnetic resonance (ce-CMR) or electroanatomic map (EAM)-and sustained monomorphic VT documented by 12-lead ECG or implantable cardioverter defibrillator (ICD) electrograms. Patients with ventricular arrhythmias caused by reversible causes were excluded. All patients provided written informed consent to participate. The study was approved by the Local Ethics Committee.
Preprocedural Evaluation
Each patient received a complete clinical evaluation. Before the indexed ablation procedure, all patients underwent transthorathic or transesophageal echocardiogram to rule out atrial or LV thrombus and to evaluate LV function. Whenever possible, 3-Tesla ce-CMR was acquired to identify the scar presence and to merge the images with those obtained by EAM. In the absence of ce-CMR or when epicardial ablation was anticipated, a computed tomographic scan was acquired to merge images. 11
VT Ablation Procedure
Procedures were performed under conscious-sedation anesthesia (midazolam and fentanyl) or general anesthesia when epicardial access was anticipated. Invasive arterial pressure was obtained by radial artery cannulation. After femoral venous access, a multipolar diagnostic catheter was positioned at the right ventricular (RV) apex. Endocardial access to the LV was obtained by single transseptal puncture (BRK needle; Medtronic Inc, Minneapolis, MN), after which heparin was intravenously administered to maintain the activated clotting time of >250 seconds. Epicardial mapping and ablation were performed when preprocedural ce-CMR showed epicardial scar, endocardial mapping did not identify subendocardial scars, ECG of clinical or induced VT suggested epicardial origin, 12, 13 or endocardial ablation was unsuccessful. Any pericardial adherences were removed via subxiphoid access by a cardiac surgeon in the electrophysiology laboratory or using a steerable sheath (Agilis St Jude Medical, St Paul, MN). The procedure followed a 4-step protocol ( Figure 1 ).
First Step: Substrate Mapping and CC Identification/Classification
Transseptal LV access was achieved, and manipulation of the ablation catheter was assisted by a steerable sheath (Agilis St Jude Medical, St Paul, MN). Retroaortic approach was used for endocardial LV mapping in 10 (9.9%) patients. High-density EAM of LV was obtained during stable sinus rhythm using the CARTO system (Biosense Webster, Diamond Bar, CA) in 96 patients and Ensite Navx (St Jude Medical, St Paul, MN) in 5 patients. Bipolar electrograms were filtered from 30 to 250 Hz. Scar areas were identified using standard voltage cut-off values for dense scar (<0.5 mV) and border zone (BZ; <1.5 mV). 
WHAT IS KNOWN
• Substrate-guided approaches to ablation of scar-related ventricular tachycardia (VT) often allow successful ablation without the need for VT mapping, but optimal targets and sequence of ablation when combined with mapping during VT are uncertain.
• We previously showed that targeting conducting channels based on timing of delayed electrogram components during sinus rhythm (dechanneling) was effective in right ventricular cardiomyopathy.
WHAT THE STUDY ADDS
• In patients with left ventricular scar-related VT, ablation started with dechanneling, and more than half of patients were free of inducible VT after this step. Additional ablation for those with inducible VT rendered a total of 78% of patients free of inducible VT.
• Abolition of VT by scar dechanneling alone identified patients with better 2-year outcomes.Starting with dechanneling as a substrate-guided approach adequately treats half of patients while requiring less ablation.
Electrograms with delayed components (E-DCs) were tagged and dichotomously classified as entrance or inner CC points, depending on delayed-component precocity during sinus rhythm. The CC entrance was defined as the E-DC with the shortest delay between the far-field component of healthy/BZ muscle (low frequency, usually high voltage) and local component (delayed, high frequency, usually fractionated and low voltage) corresponding to the local activation of myocardial fibers in the scar (Figure 2 ). To avoid targeting healthy tissue beyond the scar area, CC entrances were tagged in a zone with 0.5 to 1.5 mV voltage ( Figure 2 ).
Image integration between preacquired computed tomography or ce-CMR, when available, was performed with CartoMerge software (CartoMergeR® Image Integration Software Module; Biosense Webster, Inc, Diamond Bar, CA).
Second Step: CC Elimination
Procedural end point at this step was radiofrequency elimination of all identified CCs by radiofrequency ablation at the CC entrance during sinus rhythm (scar dechanneling), using an externally irrigated 3.5-mm tip ablation catheter (Thermocool, Navistar, Biosense Webster) with 45ºC temperature control, 50-W power limit, and 26 to 30 mL/min irrigation rate (40 W and 17 mL/min at epicardium). Each radiofrequency application lasted 30 to 60 seconds, depending on elimination of the DC, and abolition/persistence of CC electrograms was checked with the ablation catheter. If needed, a new application was performed at the closest site having CC-entrance characteristics on E-DC until the entrance was blocked. CC-entrance conduction block was considered in cases of (1) CC-inner point disappearance or automaticity with exit block or (2) delayed activation of CC inner points, usually with the activation sequence in reverse order ( Figure 3 ). Although the second criterion cannot exclude conduction delay in the targeted entrance, radiofrequency was moved to another entrance when observed, to limit the radiofrequency delivery, and came back to the same entrance if the channel isolation was not achieved. Backup radiofrequency applications were delivered inside the core scar area when radiofrequency lesions at the CC entrance did not eliminate internal E-DCs. If BZ tissue with E-DCs between scar/mitral annulus was identified, a short ablation line was used to achieve the end point.
Third Step: Remapping and Residual CC Ablation
Remapping was used to confirm the elimination of all CCs and to check for residual E-DCs, focusing on the scar area and attempting to match the mapping density of the initial EAM. Residual E-DCs identified by remapping were targeted with the same approach (target and radiofrequency ablation setup) used during initial mapping and ablation ( Figure 4 ). Posterior view of the epicardial bipolar voltage electroanatomic map from a patient with nonischemic cardiomyopathy. Normal myocardium (voltage, >1.5 mV) is coded in purple, dense scar (<0.5 mV) in red, and border zone (0.5-1.5 mV) in blue, yellow, and green. Electrograms with delayed components were classified as entrance (black dots, 1 and 5) or inner (blue dots, 2, 3, 4) conducting channel points, depending on delayed-component lateness during sinus rhythm. Electrograms within a submitral conducting channel are shown (1) (2) (3) (4) (5) . Only electrograms 1 and 5 were targeted for ablation (red dots). MA indicates mitral annulus; and RV, magnetic resonance imaging-derived right ventricle.
Figure 3.
Recordings showing the 3 types of response observed during radiofrequency (RF) application (in sinus rhythm) at the conducting channel (CC) entrance when conduction block was obtained. A, The surface ECG leads (I, II, III, aVR, aVL, and aVF) and intracardiac bipolar signals from the ablation catheter from the distal (d-2, placed at a CC entrance into the scar) to the proximal (3 and 4) dipoles. When RF application started (RFon), the CC activation sequence of the delayed electrograms moved from the distal to the proximal dipole. After a few seconds, a reversed order of the activation sequence was observed because of a conduction block at the CC entrance. B, The surface ECG leads (aVL and aVF) and intracardiac bipolar signals from the right ventricular (RV) apex catheter and distal dipole of the ablation catheter (Map) placed inside the scar area over a CC path. The recording was obtained after RF application at the CC entrance. Automaticity in the CC path with exit block to the normal myocardium is observed. C, The surface ECG lead (aVF) and intracardiac bipolar signals from the ablation catheter from the distal (d-2, placed at the CC entrance into the scar) to the proximal (3 and 4) dipoles. When RF application started (RFon), a CC activation sequence of the delayed electrograms from the distal to the proximal dipole was observed. Seconds after RF application started (RFon), the inner CC electrogram disappeared (*).
Fourth Step: Inducibility and Residual VT Ablation
Programmed RV stimulation from the RV apex, with 3 basal cycle lengths (600, 500, and 430 ms), ≤3 extraventricular stimuli decremented until refractoriness or 200 ms, and burst pacing ≤200 ms, was used for VT induction, without isoproterenol infusion. The protocol was stopped when completed or when VT/ventricular fibrillation was induced. Overdrive pacing was used before electric cardioversion to stop VT. Induced VT was considered the clinical VT, comparing 12lead electrocardiographic morphologies, cycle lengths, and intracardiac electrogram morphologies.
In the case of residual-sustained monomorphic VT induction, this VT was targeted for ablation by mapping/pacing techniques during VT (if tolerated) or during sinus rhythm (if untolerated/unsustained). Inducibility was checked after each induced VT was ablated.
Procedural Success
Induction protocol results were used to evaluate the procedural success. Acute success was reported both for patients needing scar dechanneling alone (no further VT mapping needed because they became noninducible) and for those needing the complete procedure, including residual VT ablation. Noninducibility was considered when sustained monomorphic VT was not inducible.
The absence/persistence of E-DCs that could not be eliminated was also reported.
Follow-Up
The end point was the occurrence of any sustained ventricular arrhythmia episode or sudden cardiac death (SCD). Each follow-up visit, at 1 month and every 6 months thereafter, included ICD interrogation and clinical status evaluation. Two investigators (and a third in cases of discrepancy) evaluated each stored arrhythmia episode. Ventricular arrhythmia episodes in non-ICD patients were collected from all types of ECG registry/monitoring.
Statistical Analysis
Values are expressed as percentage, mean±SD, or median (interquartile range). t test was used to compare continuous paired (endo versus epicardial and map versus remap electroanatomical data) and unpaired data (clinical and electrophysiological variables between ischemic versus nonischemic patients and with complete versus incomplete CC ablation) and Wilcoxon signed-rank test and Mann-Whitney U test for non-normally distributed data. We have performed the comparison of the characteristics of the bipolar electrograms with nested ANOVA methodology. Kaplan-Meier analysis was used to estimate event-free survival probabilities and log-rank test for between-group comparison. Variables selected from the univariate analyses (P≤0.10) were entered into multivariable Cox proportional hazards regression models to estimate predictors of VT recurrence. P<0.05 was considered significant. Statistical analysis was performed using PASW Statistics 18.0 software (SPSS Inc, Chicago, IL).
Results
Patient Sample
The sample included 101 (41%) of 246 patients who underwent any ventricular arrhythmia ablation during the study period. Baseline patient characteristics are summarized in Table 1 . An ICD was implanted in 53 (52.5%) patients before their referral for ablation, in 29 (28.7%) patients post ablation, and 19 (18.8%) patients did not receive an ICD. For image fusion purposes, 39 (38.6%) patients underwent preprocedural ce-CMR and 24 (23.8%) patients underwent a computed tomographic scan.
Ablation Procedure
The mean procedure duration and fluoroscopy time were 227±69 minutes (range, 90-480 minutes) and 18±8 minutes (range, 2-42 minutes), respectively.
First Step: Substrate Mapping and CC Identification/Classification
Substrate mapping during sinus rhythm as a first step was precluded in 6 (5.9%) patients with incessant VT or frequent repetitive VT episodes, which required starting with conventional VT activation/entrainment mapping and ablation. In all other patients (94.1%), the procedure began with substrate mapping (data summarized in Table 2 ). The mean number of points acquired to build the endocardial and epicardial EAMs was 481±187 and 486±218, respectively.
Epicardial mapping was attempted in 31 (30.7%) patients and succeeded in 27 (26.7%), with epicardial access obtained at the beginning of the procedure in 18 (17.8%) patients and after failed endocardial VT ablation in 9 (8.9%) patients. In 2 of these patients, only the epicardium was mapped because of no endocardial scarring on the voltage map from a previous VT ablation attempt (another institution) or ce-CMR.
Electrogram characteristics of the endocardial and epicardial CCs are summarized in Table 3 . CC-entrance electrograms on the lateral scar edge showed significantly later delayed-component lateness with respect to the beginning of the QRS complex, compared with those located at the septal scar border ( Figure 5 ). The amplitude of the DC of the CC electrograms tended to be greater in epicardial scars, without differences in lateness compared with the QRS-complex onset.
Second Step: CC Elimination
Complete scar dechanneling could be achieved in 85 (84.2%) patients. The median endocardial and epicardial CC-entrance electrograms targeted for ablation were 8 (4-13) and 6 (3-10), respectively, per patient. More CC-entrance electrograms were Non-normally distributed variables are presented as median and interquartile range (25th and 75th percentiles). AAD indicates antiarrhythmic drugs; CC entrance EG, conducting channel entrance electrogram (the CC-EG with the shortest local activation time of the near-field); CL, cycle length; endo, endocardial; ICD, implantable cardioverter defibrillator; LVEF, left ventricular ejection fraction; SD, scar dechanneling SMVT; sustained monomorphic ventricular tachycardia; and VT, ventricular tachycardia.
*Sum of endo and epicardial CC-EG. †Noninducibility of any SMVT at the end of the procedure.
targeted for ablation on the endocardium in ischemic patients when compared with nonischemic patients (10 [5-10] versus 3 [1] [2] [3] [4] [5] [6] [7] ; P<0.001); there were no differences between them on the epicardium (5 [3-8] versus 8 [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] ; P=0.611). A median of 18 (9-28) endocardial and 8 (4-14) epicardial radiofrequency applications per patient was necessary for elimination of all the E-DCs identified. Short linear ablation lesions were created in 21 (20.8%) patients, most of them (66.6%) were between a scar and the mitral annulus; none were created intrascar. Table 2 summarizes radiofrequency ablation data.
Third Step: Remapping and Residual CC Ablation
A mean of 567±327 points was acquired during endocardial remapping. Mean scar area identified during remapping (75±45 cm 2 ) was larger than that of the first map (52±39 cm 2 ), P<0.001. The epicardial remap (524±417 sites) also had a larger scar area than the first map (71±52 versus 44±41 cm 2 ; P=0.009). The mean number of endocardial and epicardial CC electrograms per patient decreased from 42 (25-72) and 52 (26-69) in the map to 10 (3-18) and 13 (0-26) in the remap (P<0.001 and P=0.001), respectively. Eliminating these residual CC electrograms required a median of 7 (4-15) endocardial and 3 (0-9) epicardial radiofrequency applications. Complete scar dechanneling could not be achieved in 16 (15.8%) patients because of the proximity of coronary arteries (1 patient), phrenic nerve capture (1 patient), or conduction system (His bundle, left bundle branch) electrogram recording at the target site for radiofrequency applications (5 patients), or simply, because E-DCs could not be eliminated despite repeated radiofrequency delivery (9 patients).
Fourth step: Inducibility and Residual VT Ablation
After complete scar dechanneling, 55 (54.5%) patients were noninducible; in the 46 inducible patients, 71 of 75 residual sustained monomorphic VTs were targeted for ablation. Ablation was guided by mapping/pacing during 40 VTs and by pacemapping in 31. The mean cycle length of residual VTs was 335±88 ms.
Endocardial ablation was successful in 38 (50.7%) residual VTs, epicardial ablation in 13 (17.3%), and ablation failed in 20 (26.7%) VTs. Therefore, the noninducibility of sustained monomorphic VTs increased from 54.5% after scar dechanneling to 78.2% after residual VT ablation. The cycle length of epicardially ablated VTs did not differ significantly from endocardially ablated VTs (339±86 versus 349±102 ms, respectively; P=0.284).
Procedure-Related Complications
Acute complications potentially related to the procedure occurred in 7 (6.9%) patients; there were no procedure-related Figure 5 . Example of a patient with an old inferior infarction with aneurysm. A highdensity map was obtained, with mapping focused on the area of interest. Standard voltage thresholds were used to identify the scar area. Electrograms (EGMs) with delayed components are tagged in black when they had the appearance of a conducting channel (CC) entrance (delayed component with the shortest delay, usually fused with the far-field electrogram) and in blue when they had the appearance of an inner CC part (delayed component with longer delays with respect to the far-field electrogram). The relationship to the beginning/end of the QRS complex is independent of identifying a CC entrance vs inner point, which depends mainly on septal vs lateral location in the ventricle during sinus rhythm. In the example, local electrograms of lateral entrance (left) are inscribed at the end of the QRS, whereas at septal entrances (right), local electrograms are inside the QRS. Bottom, Inner CC electrograms recorded inside the scar are shown. MA indicates mitral annulus. Two patients had cardiac tamponade requiring pericardiocentesis after endocardial ablation. Two patients presented with complete atrioventricular block; one of them (with previous left bundle branch block) underwent CRT-D implantation, and the other had permanent atrial fibrillation and a previously implanted single-chamber ICD. In the first weeks of followup, 2 patients with epicardial ablation had postprocedural pericarditis with pericardial effusion, one of them requiring pericardiocentesis. One patient had transient ischemic attack without sequelae and another with nonischemic cardiomyopathy had cardiogenic shock, and symptomatic phrenic nerve palsy was detected during follow-up in 1 patient who underwent epicardial radiofrequency ablation.
Table 3. Conducting Channel Electrogram Characteristics, Depending on the Endocardial vs Epicardial Location and Septal vs Lateral Position at the Scar Edge
Follow-Up
After a median (interquartile range) follow-up of 21 (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) months, recurrences of sustained ventricular arrhythmia episode or SCD were observed in 27 (26.7%) patients. Oral amiodarone was prescribed at some point in 28 (27%) patients. There were no significant differences in amiodarone usage before ablation neither in inducible versus noninducible patients after scar dechanneling (34.8% versus 21.8%; P=0.147), in amiodarone administration after the procedure in patients with or without VT recurrence (34.6% versus 25.3%; P=0.362), nor in patients who died versus survivors (22.3% versus 28.3%; P=0.699). ICD interrogation showed that 20 (19.8%) patients had appropriate therapies. Of these, 10 (9.9%) received ICD shocks and 10 (9.9%) had VT episodes that were terminated by antitachycardia pacing. Cycle length of the recurrent VTs during follow-up exceeded that of preprocedural clinical VTs (399±78 versus 342±86 ms, respectively; P=0.049). Four (3.9%) patients experienced VTs that were monitored in the slow VT detection zone and did not receive therapy. Two patients without ICD implantation, because of comorbidities and low life expectancy, had VT recurrence; one of them required reablation. Nine (8.9%) patients died of various causes during followup: 4 of advanced heart failure (4%), 1 of SCD (severe comorbidities, low life-expectancy), 1 of arrhythmic storm (despite ICD), 2 of noncardiac death (acute renal failure with heart failure decompensation and nosocomial pneumonia, respectively), and cause of death is not available for 1 patient. Survival curve analysis ( Figure 6 ) showed higher end pointfree survival for patients with complete CC-electrogram elimination (log-rank test P=0.001).
Scar Dechanneling as the First Step
Scar dechanneling was the first step and the only ablation strategy needed for obtaining noninducibility in 54.5% of patients; in consequence, the procedure duration was shorter than that of patients requiring residual inducible-VT ablation (213±64 versus 244±71 minutes, P=0.027).
Baseline characteristics and procedure-related data of these patients and those needing residual inducible VT ablation are summarized in Table 5 . Despite having no significant differences in left ventricular ejection fraction and myocardial scar area, patients needing only scar dechanneling had fewer endocardial E-DCs (36±29 versus 50±32; P=0.04), required fewer radiofrequency applications (19±11 versus 27±18; P=0.01), and less frequently had incomplete CC-electrogram elimination (7.3% versus 26.1%; P=0.01). Most importantly, they had higher 2-year probability of overall (95% versus 89%) and event-free survival (80% versus 62%; Figure 6 ).
Redo Procedures
A redo procedure using the same ablation protocol was performed in 11 of the 27 patients who reached the primary end point (8 ischemic and 3 nonischemic cardiomyopathies) at a median of 11 (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) months after the index ablation. The indication for the redo procedure was appropriate ICD therapy in 6 patients, slow VT with no therapy in 4 patients, and VT requiring external cardioversion in 1 patient without ICD. The mean VT cycle length was 401±96 ms. Nine (82%) of these 11 patients required epicardial ablation, 5 needed a combined endocardial/epicardial substrate ablation, and ablation was exclusively epicardial in 4 patients. In 2 patients, surgical subxiphoid access was necessary. In addition to substrate ablation, 7 more VTs were targeted and ablated during the redo procedures, 6 of them from the epicardium.
A third procedure was necessary in 2 patients, both in the first month after reablation. Both patients had incessant VT that required high radiofrequency energy delivery, in the LV septum in an ischemic patient with anterior aneurysm and in epicardial LV summit in a patient with dilated cardiomyopathy. During a median follow-up of 19 (11-28) months, 15 (14.9%) patients reached the end point of any sustained ventricular arrhythmia episode or SCD after 1.13 procedures per patient.
Discussion
Main Findings
This study shows that substrate ablation with the scar dechanneling technique as the first step of the ablation protocol (before any VT induction/ablation attempt) renders more than half of the patients with LV scar-related VTs noninducible. These patients can benefit from starting and finishing the procedure in sinus rhythm, with lower procedural requirements (procedure duration, radiofrequency delivery), fewer complications, no hemodynamic instability, and a much lower chance of direct current cardioversion/defibrillation. In the long term, a patient subgroup (ie, noninducible after scar dechanneling) is identified that, despite a similar clinical profile (age, VT cycle length, left ventricular ejection fraction, scar size), have a lower probability of VT recurrences or sudden death (16.4% versus 37%, P=0.018) and lower mortality (3.6% versus 15.2%, P=0.042), compared with patients needing residual inducible VT ablation. The differences in procedure requirements and better outcomes likely reflect that patients needing scar dechanneling alone have a more accessible substrate.
Although other substrate-guided VT strategies using different ablation targets have been described, they systematically included an induction protocol, and ablation of sustained VT, if well tolerated, before substrate ablation. [3] [4] [5] The present findings suggest substrate ablation as the preferred first step, regardless of the technique used.
CC Identification and Ablation
CCs have been reliably identified in RV dysplasia, 7,9 ischemic, 6, 14 and also in nonischemic 8 cardiomyopathy. Therefore, it could be assumed that they are present in every scar-related VT. In this study, although differences in scar distribution depending on cardiomyopathy type have been noted, the technique has been equally applicable in the different substrates.
The study definition of a CC-entrance electrogram was the same as that used for scar dechanneling in arrhythmogenic RV dysplasia 7,9 because it does not depend on activation time or the voltage of the DC. The definition only takes into account the relative position of the local electrogram in the CC activation sequence. The CC-entrance electrograms were mostly located at the scar edge, as in the case of arrhythmogenic RV dysplasia. Dichotomization of E-DCs into entrance and inner points, without the need for tracking along every single CC path, facilitated mapping because CCs are 3-dimensional and a planar construct on a single endo/epicardial surface is an oversimplification and sometimes not possible. 14 Various definitions have been used to identify the target electrogram in substrate ablation, [3] [4] [5] 15, 16 mainly based on the local electrogram delay. As shown in this study, the delay of the local electrogram with respect to the beginning of the QRS is not critical to be qualified as a CC-entrance, as this delay mostly depends on the septal versus lateral position at the scar edge. With respect to the lateness or separation between the DC and the far-field electrogram, the definition used for the CC entrance makes it nonquantifiable because fusion is usually present. This supports a recent study showing that local electrogram lateness is affected by its location with respect to the septum, other early-to-activate regions, and the scar margin. 17 No significant differences between endocardial and epicardial CCs were observed with respect to activation time. However, a higher voltage of the local electrogram was found on the epicardium, which could be explained by the higher scar heterogeneity (BZ percentage of scar) at the subepicardial LV wall in ischemic patients 14 because the bipolar voltage of the BZ areas is higher than that of the scar core areas. 18 With respect to the radiofrequency energy delivered, although populations are not fully comparable between different studies, 28±16 minutes of radiofrequency application with scar dechanneling favorably compare with the requirements of other substrate ablation strategies, such as linear ablation 19 or scar homogenization 4 and approximate local abnormal ventricular activity ablation. 5 It also has been recently confirmed that targeting the earlier late potentials contained in the CCs (CC-entrance) can eliminate inner CC electrograms and homogenize the scar without extensive ablation, increasing the efficiency of the ablation methodology used. 10
Outcomes
The 26.7% event rate for the study end point of any sustained ventricular arrhythmia or SCD is in the lower range of previously published studies in which the end point was complete substrate elimination using different ablation targets, 4, 5, 20 and it is better than previous studies on standard VT ablation. 21 However, the most attractive finding is the possibility of identifying a large subgroup of patients with a low event rate when complete substrate ablation is the first step taken, before any VT induction/ablation attempt. These patients maintain sinus rhythm during the whole procedure because they become noninducible after scar dechanneling. This subgroup cannot be distinguished by clinical data (except for the lower proportion of VT storm before the procedure), echocardiographic characteristics, or scar dimensions from those who will remain inducible. However, they have fewer E-DCs and require fewer radiofrequency applications to obtain complete CC-electrogram elimination, which in turn is the only independent predictor for VT recurrence or SCD.
Interestingly, 82% of patients undergoing a redo procedure required epicardial ablation. If epicardial mapping/ablation is considered for the first ablation procedure in appropriate patients (eg, nonischemic patients with evidence of epicardial scar or ischemic patients with transmural scars), there is a potential margin for improved outcomes. 22 In fact, in this study, epicardial mapping was significantly associated with a lower event rate for the primary end point in univariate analysis. The left ventricular ejection fraction did not differ between patients needing scar dechanneling alone versus those requiring residual inducible VT ablation nor was it a predictor of clinical outcomes during follow-up. Primary prevention studies have shown that the presence, quantity, and characteristics of the arrhythmogenic substrate (ie, the scar and its heretogeneity) provide the strongest predictor of arrhythmic events. 23 Therefore, it should not be surprising that the only independent predictor of clinical outcomes after ablation is the variable most closely related to incomplete substrate elimination (ie, incomplete CC-electrogram elimination). Left ventricular ejection fraction was not a predictor of recurrence in other studies on VT substrate ablation that have attempted complete elimination of the arrhythmic substrate. 4, 5 
Limitations
This study could not determine whether some of the benefits observed-lower procedure requirements, fewer complications, and better outcomes for patients needing only the scar dechanneling technique-are exclusively because of substrate ablation as the first step during the procedure or involve other conditions that permit the use of this strategy (ie, the absence of incessant VT) or uncontrolled determinant factors not taken into account. Improved outcomes observed in patients for whom scar dechanneling alone achieved noninducibility suggest that this subgroup had a more accessible substrate. A small proportion of patients with clinical VTs could be noninducible before ablation; the lack of a basal induction protocol limits the evaluation of the acute effect of substrate ablation. However, taking into account that scar dechanneling seeks the complete elimination of all the substrate, the induction or not at the beginning of the procedure will not change the ablation set. Therefore, testing only the acute effect of scar dechanneling might not provide sufficient justification to perform the initial VT induction protocol, which increases the procedure duration and is not free of complications. Finally, because substrate mapping was performed during intrinsic rhythm in the vast majority of patients, we did not analyze the effect of different activation wavefronts (ie, intrinsic rhythm versus paced rhythm) on CC entrance location and characteristics.
Conclusions
Scar dechanneling alone results in low recurrence and mortality rates in more than half of patients despite the limited ablation extent required. Residual inducible VT ablation improves acute results, but patients who require it have worse outcomes. Recurrences are mainly related to incomplete CC-electrogram elimination.
